Nonagen Therapeutics Corp.

DUBLIN, Sept. 11, 2023 /PRNewswire/ -- The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. In the ever-evolving landscape of the diagnostic industry, immunoassay is emerging as a steadfast workhorse, finding new relevance driven by the demands of the ongoing pandemic. The need for rapid, easily accessible diagnostics has propelled immunoassay to the forefront, as it adapts and advances in response to shifting market dynamics. Advancements in genetic knowledge are opening up new avenues for immunoassay technologies, with multiplex capabilities becoming the standard. This transformation extends to rapid diagnostics, point-of-care solutions, biomarker exploration, and the expanding consumer market, while traditional immunoassay methods continue to hold a strong position within the growing realm of clinical diagnostics. Within the realm of immunoassay instrumentation, multiple factors are fueling growth, including ongoing diagnostic breakthroughs, the retirement of older instruments driven by evolving technologies, wider consumer adoption, and the maturation of immunity-related technology. However, these opportunities are not without their challenges. Heightened competition is exerting downward pressure on prices, while the threat from PCR-based instruments looms. Lower barriers to entry and potential drawbacks associated with wellness trends also present limitations to growth. This dynamic landscape is characterized by enduring instruments, industry structures in flux due to declining instrument costs, and meticulous instrument specifications, which play a pivotal role in shaping the field. Innovations like CRISPR diagnostics further contribute to the evolving immunoassay landscape. With profiles of over 60 companies, spanning both large and small players in this field, this comprehensive report offers invaluable insights into the pitfalls and opportunities that define the immunoassay industry. It equips stakeholders to make informed investment decisions and valuations, providing the latest data to navigate this ever-changing landscape with confidence. Key Topics Covered: Industry Overview Players in a Dynamic Market Academic Research Lab Diagnostic Test Developer Instrumentation Supplier Chemical/Reagent Supplier Pathology Supplier Independent Clinical Laboratory Public National/regional Laboratory Hospital Laboratory Physicians Office Lab (POLS) Audit Body Certification Body The Clinical Laboratory Market Segments Traditional Market Segmentation Laboratory Focus and Segmentation Hospital Testing Share Economies of Scale Hospital vs. Central Lab Physician Office Lab's Physician's and POCT Immunoassay - Markets and Discussion Instruments - Genetics changes the picture RIA - A Technology Shows its Age Immunoassay vs. PCR vs. Sequencing - A See Saw Battle The Smart Shrinking Instrument - Serious Implications Research Funding and Capital Expense - Instrument Pooling Multiplex vs. POC - A Tradeoff Analysis Reagents and Kits - Genetics changes the picture Bigger Test Menus a Boon for Kit Market Physician Office Labs - A New Frontier Rapid and POCT to Threaten Instrument Markets OTC and DTC - Huge Market Potential Economies of Scale. Going Away? Lower Barriers to Entry for Instruments/Analyzers Miniturization and Technology Drive Acquisition Immunoassay Recent Developments Recent Developments - Importance and How to Use This Section EDP Biotech, New Day Diagnostics to Merge Sorrento Therapeutics Nabs Contract for Dx Platform Beckman Coulter Diagnostics DxI 9000 Access Immunoassay Analyzer Qorvo Eyes Multiplex Immunoassay BioMerieux Launches New Products Senzo to Commercialize Infectious Disease Lateral Flow Tests Nanomix Plans Instrument, Test Launches Startup GLX Analytix Prepares for Commercialization Nonagen Gets CE Mark for Bladder Cancer Immunoassay Qualigen Acquires Majority Stake in NanoSynex Saladax Biomedical Using Immunoassay Dx Prolight Diagnostics to Acquire Psyros Diagnostics Quidel to Acquire Ortho Clinical Diagnostics FDA Grants EUA to Xtrava Health Alamar Biosciences Develops Immuno-Sandwich Platform FDA grants breakthrough device to multiplex immunoassay Quidel, Beckman Settle Cardiac Immunoassay Dispute BGI Americas, Advaite Form SARS-CoV-2 Testing Partnership BioMerieux Gets CE Mark for Three Dengue Immunoassays COVID-19 Portfolio to Accelerate At-Home Infectious Disease Testing Roche Diagnostics Expanding Testing Portfolio in 2021 PerkinElmer Long-Term Outlook Quidel Updates Outlook for C19 Testing Dx Companies Look at Multiplex Tests for SARS-CoV-2, Influenza Becton Dickinson and NAT Diagnostics Acquisition Market Trends Factors Driving Growth Diagnostic Factors Changing Technologies Spur Early Instrument Retirement Consumer Channels Open Wider Immunity Technology Comes of Age Factors Limiting Growth Increased Competition Lowers Price Threat from PCR Based Instruments Lower Barriers to Entry Wellness has a downside Immunoassay Instrumentation Instrumentation Tenacity Declining Cost of Instruments Changes Industry Structure LISTING of INSTRUMENT SPECIFICATIONS Immunoassay - CRISPR Diagnostics Market Guides Immunoassay Market - Strategic Situation Analysis Guide for Executives, Marketing, Sales and Business Development Staff Guide for Management Consultants and Investment Advisors Market Definition Immunoassay Markets Definition In This Report Enzyme Based Immunofluorescence Chemiluminescence DNA/NAT RIA & Other Reagents/Kits, Analyzers, Software & Services Infectious Disease Auto Immune Endocrinology Oncology Cardiology Other Specialty Market Definition Methodology Perspective: Healthcare and the IVD Industry Global Healthcare Spending Spending on Diagnostics Important Role of Insurance for Diagnostics Appendices United States Medicare System: Laboratory Fees Schedule The Most Used IVD Assays The Highest Grossing Assays Profiles of Key Companies Abbott Laboratories Abcam Abionic Accel Diagnostics Applied BioCode Arlington Scientific Arrayit Corporation Atomo Diagnostics Aureum Diagnostics Aurora Biomed Autobio Diagnostics AVIVA Systems Biology Awareness Technology Axis-Shield Diagnostics Ltd. Beckman Coulter Diagnostics Becton, Dickinson and Company Biocartis Biomatik bioMerieux Diagnostics Bioneer Corporation Bio-Rad Laboratories, Inc. BioTek Instruments Boditech Med, Inc Boster Biological Technology Diamedix (Erba Diagnostics) Diasorin S.p.A. Dynex Technologies Enzo Biochem Eurofins Scientific FUJIFILM Wako Diagnostics Fujirebio Gold Standard Diagnostics Grifols Hycor Biomedical Immunodiagnostic Systems (IDS) Immunodiagnostik AG Inova Diagnostics JR Biomedical Luminex Corp Maxim Biomedical Mbio Diagnostics Meso Scale Discovery Millipore Sigma Mindray Molecular Devices MP Biomedical Operon Ortho Clinical Diagnostics Perkin Elmer Qiagen Quidel R&D Systems Randox Toxicology Roche Molecular Diagnostics SD Biosensor Siemens Healthineers Sysmex Tecan Thermo Fisher Scientific Inc. TOSOH Bioscience Veredus Laboratories Vircell YD Diagnostics Zhejiang Orient Gene Biotech Scope of the Report Global Market by Application Endocrinology Applications Immune Applications Oncology Applications Infectious Disease Applications Cardiology Applications Other Applications Immunoassay by Technology Enzyme Flourescence Chemiluminescence Nucleic Acid Rapid/POC Other Technology Immunoassay by Product Instrument Reagents Services Immunoassay by User Hospital Outpatient Lab POC/Other 12 Vision of the Future of Immunoassay For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

LOS ANGELES, April 27, 2023 /PRNewswire/ -- Nonagen Bioscience, a cancer diagnostics company, today announced that Timothy "TJ" Johnson has been named Executive Chair of the Nonagen Bioscience Corporation. Mr. Johnson has nearly 30 years of executive leadership experience in the life sciences industry. Timothy "TJ" Johnson has been named Executive Chair of the Nonagen Bioscience Corporation. In his new role, Mr. Johnson will provide strategic and operational direction, collaborate with Nonagen's CEO and senior management on research and commercialization efforts, and advise on all company ventures and strategic partnerships. "We're thrilled to welcome TJ and his effective style of leadership," said Nonagen Bioscience CEO Charles Joel Rosser, MD, MBA. "Not only does he have an impressive track record of success in managing companies like ours, but he also shares our passion to bring science to bear in the fight against cancer." Mr. Johnson has held C-suite and executive-level leadership positions for several life sciences companies, including Ventana Medical Systems, Inc., a medical diagnostics company that was acquired by Roche in 2007. He spent more than 12 years as president and CEO and as a member of the board of directors at HTG Molecular Diagnostics, including leading a successful IPO in 2015. Previously, he had a career that spanned more than 10 years at Hillenbrand Industries, Inc. Mr. Johnson holds a bachelor's degree in business from Indiana University. "Nonagen Bioscience is breaking new ground in the field of cancer diagnostics with its Oncuria® liquid biopsy for the early detection and management of bladder cancer," said Mr. Johnson. "I look forward to working with this talented team to bring noninvasive diagnostic tests to healthcare providers and their patients." About Nonagen Bioscience Nonagen Bioscience is a privately held biotechnology company that is focused on globally reducing the burden of cancer with innovative diagnostics. The Los Angeles–based company is committed to bringing to the market best-in-class, noninvasive diagnostics for cancer detection, therapy choice, and disease monitoring, so patients can live better, longer lives. Nonagen's lead diagnostic for bladder cancer, Oncuria®, is available as a laboratory developed test through DiaCarta Laboratories in the United States and Canada. Nonagen Bioscience is currently seeking US Food and Drug Administration approval for Oncuria as an in vitro diagnostic test. Contacts MEDIA Jenny Sparano Vice President, Public Relations jsparano@peregrinemarketaccess.com INVESTOR RELATIONS Dave Mori Chief Business Officer mori@nonagen.com View original content to download multimedia: SOURCE Nonagen Bioscience